Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Merck : Human Longevity, Inc. Announces Agreement with Merck KGaA, Darmstadt, Germany to Engage in Cancer Biomarker Discovery in Advanced Melanoma

share with twitter share with LinkedIn share with facebook
share via e-mail
06/22/2017 | 08:46pm CEST

By a News Reporter-Staff News Editor at Clinical Trials Week -- Human Longevity, Inc. (HLI), the genomics-powered, health intelligence company, announced that the company has signed an agreement with Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, with the goal of pioneering the application of advanced genomics and expert analysis with machine learning to transform drug development and medical use of next generation therapeutics. As part of the agreement, the companies have started a joint pilot project to identify treatment response biomarker signatures in patients with advanced melanoma. Financial terms of the deal were not disclosed (see also Pharmaceutical Companies).

Cindy Collins, HLI CEO said, "Our agreement with Merck KGaA, Darmstadt, Germany will enable us to work together to discover novel insights that improve patient survival in melanoma, the deadliest form of skin cancer. With more than 230,000 new cases of melanoma diagnosed worldwide each year, and rates on the rise for the last 30 years, we believe our first pilot project is of great importance for society and look forward to working with Merck KGaA, Darmstadt, Germany to impact the treatment of melanoma."

In the pilot project, Merck KGaA, Darmstadt, Germany and HLI are working together to identify treatment response biomarkers in patients with locally advanced or metastatic NRAS mutated cutaneous melanoma that preferentially respond to Merck KGaA Darmstadt, Germany's MEK1/2 inhibitor, pimasertib. To enable this goal, HLI is generating genomic sequencing data from clinical trial participants' tumor and germline and utilizing its machine learning and analytical tools and expertise to interpret and analyze this data in the context of survival and other clinical data.

HLI is building the world's largest database of genomic, phenotypic, and clinical information. HLI has sequenced approximately 40,000 high-quality genomes and is building an unparalleled database of genomic and phenotypic integrated health records. HLI's customers include pharmaceutical and biotechnology companies, life insurance companies, large academic medical centers, physicians and individuals.

Keywords for this news article include: Pharmaceutical Companies, Cyborgs, Genetics, Melanoma, Oncology, Merck KGaA, Machine Learning, Cancer Biomarkers, Carcinoma Biomarkers, Human Longevity Inc., Emerging Technologies, Diagnostics and Screening.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK KGAA
06/22 MERCK : Human Longevity, Inc. Announces Agreement with Merck KGaA, Darmstadt, Ge..
06/15 MERCK KGAA : Darmstadt, Germany, Strengthens Immuno-Oncology Portfolio through E..
06/14 PFIZER : German Merck Doubles Down On Dual-Acting Cancer Agents
06/13 Progesterone Market 2017 - Pfizer, Solvay, ASEN, SENZU, Actavis, Merck Serono..
06/09 MERCK : EMD Serono Honors World MS Day by Launching Care Partner Survey with IAC..
06/09 MERCK KGAA : Darmstadt, Germany, Selects illusive networks' Deceptions Everywher..
06/09 MERCK KGAA : Darmstadt, Germany Licenses Selexis SUREtechnology Platform for Imm..
06/04 MERCK : Strengthens Immuno-Oncology Portfolio through Expansion of F-star Collab..
06/02 MERCK : SCHOOLS Memorial Park School to host STEM Fair
06/01 MERCK : EMD Serono to Present Data Highlighting Investigational Cladribine Table..
More news
Sector news : Specialty & Advanced Pharmaceuticals
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
06/15 Therapy Focus - Lupus Hopes Build But Data Remain On The Distant Horizon
06/13 German Merck Doubles Down On Dual-Acting Cancer Agents
06/06 Merck Reveals Its Gastric Cancer Hand
06/05 Deciphering The Immunology Combo Avalanche
05/18 Merck's (MKGAF) on Q1 2017 Results - Earnings Call Transcript
Financials (€)
Sales 2017 15 598 M
EBIT 2017 3 382 M
Net income 2017 1 840 M
Debt 2017 9 581 M
Yield 2017 1,15%
P/E ratio 2017 25,79
P/E ratio 2018 22,07
EV / Sales 2017 1,54x
EV / Sales 2018 1,36x
Capitalization 14 365 M
More Financials
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 113 €
Spread / Average Target 1,9%
Consensus details
EPS Revisions
More Estimates Revisions
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA12.66%16 065
ABBVIE16.00%115 610
KYOWA HAKKO KIRIN CO L..28.74%10 787
More Results